Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2019 2020 2021 2022 2023 2024 2025
Months
January February March April May June July August September October November December
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

#Women’sMonth: A career in Sign Language interpreting proves to be full of rewards for Natasha Parkins-Maliko
2017-08-03

 Description: Natasha Parkins-Maliko new Tags: Natasha Parkins-Maliko new 

Natasha Parkins-Maliko. She
was recently awarded the Pansalb
Multilingual Award in the category:
Translation and Interpreting 2016/2017,
as recognition for her achievements
in a sixteen-year career.
Photo: Supplied

Natasha Parkins-Maliko is an alumna of the University of the Free State who graduated with a master’s in Linguistics. She is a well-rounded interpreter with a language combination of South African Sign Language-English-Afrikaans. She continued her studies and achieved an international master’s in Sign Language interpreting at the Humak University of Applied Sciences in Finland.  Natasha was recently presented with the Pansalb Multilingual Award in the category: Translation and Interpreting 2016/2017, as recognition for her achievements in a sixteen-year career.

“Winning the Pansalb Translation and Interpreting Award for 2016/2017, was for me as Kovsie a pat on the back in the true sense of the word.  The university is where I started my journey in South African Sign Language interpreting, and from then on, I never looked back,” she said.

Her interpreting career has provided many challenges, and was accompanied by great achievements along the way.

A career of fulfilment in Sign Language
“The foundation of my success was laid by my lecturers and mentors, such as Dr Philemon Akach and Emily Matabane, where I trained in the Department of South African Sign Language (SASL) at the university.”

“My determination and success is grounded in the motto, ‘Inspiring Excellence, Transforming Lives’ – a continued journey in excellence gives a renewed sense of pride for all language practitioners in South Africa,” she said.

Natasha went on to work in the deaf community for most of her career. She started as a grassroots interpreter, and is now a professional interpreter registered with SATI (South African Translators Institute). She is also a Sign Language television interpreter on SABC for content such as SABC 3 news bulletins, the budget speech, opening of Parliament, Youth Day broadcasts, January 8th statement broadcasts, MPC Reserve Bank speeches, and many more. Natasha is not only concerned with growing her career – despite her mover and shaker persona, she still takes time to volunteer her services for deaf people who do not have the financial ability to pay for interpreting.

“Winning the Pansalb Translation and
Interpreting Award for 2016/2017, was
for me as Kovsie a pat on the back in
the true sense of the word.”

The journey to excellence never stops
Over and above lecturing in Interpreting and Translation at Wits University, Natasha is still in pursuit of excellence. She is a PhD candidate in the SASL Interpreting programme at Wits University, the first of its kind in the country, and is pursuing an AIIC (International Association of Conference Interpreters) accreditation. Her aim is to put South African Sign Language interpretation on the global map.

As a role model and icon in her field, Natasha is the chairperson of the National Association of South African Sign Language Interpreters (NASASLI), the regional coordinator for the African Federation of Sign Language Interpreters (AFSLI), and the Africa regional representative on the board of the World Association of Sign Language Interpreters (WASLI).  The award presented to her is no doubt a fitting accolade and something all UFS alumni takes pride in.

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept